Overview

An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in Mucopolysaccharidosis Type II (Hunter Syndrome) Male Subjects

Status:
Not yet recruiting
Trial end date:
2028-02-28
Target enrollment:
Participant gender:
Summary
An extension of Global Phase III open-label, multicenter designed to evaluate the Long-term safety and efficacy of study drug for the treatment of the MPS II.
Phase:
Phase 3
Details
Lead Sponsor:
JCR Pharmaceuticals Co., Ltd.